Senile Purpura Clinical Trial
Official title:
Phase II Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in The Prevention and Treatment of Senile Purpura
This is an open label 6 month pilot study for male and female participants over the age of
52 that desire treatment and prevention of senile purpura of the forearms.
This study will be evaluating the effects of Adapalene 0.3% for the use in the treatment and
prevention of senile purpura.
This is a new potential use for the product Adapalene 0.3%, which is currently an FDA
approved topical treatment used for the treatment of acne.
Senile purpura is a common sign of aging that appears in the form of dark blotches on the
skin and is caused by bruising.
Older adults tend to be more prone to bruising, since as people age, their skin becomes
thinner and more fragile.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03690375 -
Broad Band Light for the Treatment and Prevention of Senile Purpura
|
N/A | |
| Completed |
NCT05037604 -
Factors Associated With Dermatoporosis
|